
Liqin Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2629846/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human apolipoprotein E isoforms are differentially sialylated and the sialic acid moiety in ApoE2 attenuates ApoE2-Al² interaction and Al² fibrillation. Neurobiology of Disease, 2022, 164, 105631.	4.4	11
2	Clusterin: a multifaceted protein in the brain. Neural Regeneration Research, 2021, 16, 1438.	3.0	11
3	Sialometabolism in Brain Health and Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 648617.	2.8	32
4	Glycolytic Metabolism, Brain Resilience, and Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 662242.	2.8	47
5	Non-invasive Brain Delivery and Efficacy of BDNF in APP/PS1 Transgenic Mice. Medical Research Archives, 2020, 8, .	0.2	14
6	Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial. Menopause, 2019, 26, 874-884.	2.0	22
7	Brain clusterin protein isoforms and mitochondrial localization. ELife, 2019, 8, .	6.0	31
8	Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor Î ² -selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause, 2018, 25, 191-196.	2.0	10
9	Estrogen receptor β deficiency impairs BDNF–5-HT 2A signaling in the hippocampus of female brain: A possible mechanism for menopausal depression. Psychoneuroendocrinology, 2017, 82, 107-116.	2.7	67
10	ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain. Alzheimer's Research and Therapy, 2017, 9, 79.	6.2	18
11	Sex differences in metabolic aging of the brain: insights into female susceptibility to Alzheimer's disease. Neurobiology of Aging, 2016, 42, 69-79.	3.1	108
12	Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase. Journal of Alzheimer's Disease, 2016, 53, 1015-1031.	2.6	17
13	ApoE2 and Alzheimer′s disease: time to take a closer look. Neural Regeneration Research, 2016, 11, 412.	3.0	51
14	Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. Journal of Alzheimer's Disease, 2015, 48, 411-424.	2.6	76
15	Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics. Ageing Research Reviews, 2015, 24, 178-190.	10.9	70
16	Early Intervention with an Estrogen Receptor Î ² -Selective Phytoestrogenic Formulation Prolongs Survival, Improves Spatial Recognition Memory, and Slows Progression of Amyloid Pathology in a Female Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 403-419.	2.6	47
17	Continuous versus Cyclic Progesterone Exposure Differentially Regulates Hippocampal Gene Expression and Functional Profiles. PLoS ONE, 2012, 7, e31267.	2.5	49
18	17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: Relevance to Alzheimer's prevention. Neurobiology of Aging, 2011, 32, 1949-1963.	3.1	121

Liqin Zhao

#	Article	IF	CITATIONS
19	Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause, 2011, 18, 1131-1142.	2.0	38
20	A Select Combination of Clinically Relevant Phytoestrogens Enhances Estrogen Receptor \hat{I}^2 -Binding Selectivity and Neuroprotective Activities in Vitro and in Vivo. Endocrinology, 2009, 150, 770-783.	2.8	82
21	WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Review of Neurotherapeutics, 2007, 7, 1549-1564.	2.8	75
22	Design, Synthesis, and Estrogenic Activity of a Novel Estrogen Receptor ModulatorA Hybrid Structure of 17l²-Estradiol and Vitamin E in Hippocampal Neurons. Journal of Medicinal Chemistry, 2007, 50, 4471-4481.	6.4	41
23	Estrogen receptor α and β differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Research, 2007, 1172, 48-59.	2.2	189
24	Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neuroscience, 2006, 7, 24.	1.9	76
25	Estrogenic Agonist Activity of ICI 182,780 (Faslodex) in Hippocampal Neurons: Implications for Basic Science Understanding of Estrogen Signaling and Development of Estrogen Modulators with a Dual Therapeutic Profile. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1124-1132.	2.5	70
26	Estrogen receptor \hat{I}^2 as a therapeutic target for promoting neurogenesis and preventing neurodegeneration. Drug Development Research, 2005, 66, 103-117.	2.9	25
27	Structure-Based Virtual Screening for Plant-Based ERβ-Selective Ligands as Potential Preventative Therapy against Age-Related Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2005, 48, 3463-3466.	6.4	85
28	Selective estrogen receptor modulators (SERMs) for the brain: Current status and remaining challenges for developing NeuroSERMs. Brain Research Reviews, 2005, 49, 472-493.	9.0	104
29	Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary bippocampal neurops, Brain Research, 2004, 1010, 22-34	2.2	222